Combined CAR T-cell Therapies: A Next Step towards Precision Oncology
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 18966
Special Issue Editor
2. Mildred Scheel Early Career Center, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany
Interests: CAR T-cells; bispecific antibodies; (radio)immunotherapy and imaging of tumors
Special Issue Information
Dear Colleagues,
Chimeric antigen receptor (CAR) T cell therapy is a rapidly growing field with unparalleled clinical success rates for the treatment of patients with relapsed or refractory B cell malignancies. However, translation toward other tumor entities is still limited as CAR T-cells alone might not be sufficient to elicit durable responses. Reasons are multifaceted and include, e.g., the lack of true tumor-specific markers, the immunosuppressive tumor microenvironment, tumor heterogeneity, and the selection and induction of therapy-resistant tumor cell clones or previous treatment modalities. To overcome these hurdles and to boost CAR T-cell cytotoxicity, various combinatorial or multiple tumor targeting approaches are intensively investigated, but combinations with other treatment modalities, such as standard chemo- or radiotherapy, small molecule inhibitors or targeted therapies, also play an increasingly important role. From a clinical perspective, even the combination of CAR T-cell therapy with non-invasive, molecular imaging is a highly promising strategy for improved patient stratification and guidance of appropriate patient-specific treatment. The implementation of imaging tools will allow both target verification to periodically assess molecular responses and capture the dynamic behavior of living drug therapies. This may facilitate accurate diagnosis, prognosis, and treatment planning, including interventions and dose calculations.
This Special Issue aims to cover recent advances in combined CAR T-cell approaches as well as new imaging methods and therefore seeks for review or original manuscripts addressing one of the aforementioned (or related) topics.
Dr. Claudia Arndt
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CAR T-cells
- cellular therapies
- combination therapy
- molecular imaging
- multiple tumor targeting
- combinatorial CAR design
- radiotherapy
- chemotherapy
- targeted therapy
- small molecules
